› $150,000,000 verdict in personal injury case
The evidence weighing the benefits and risks of hormone replacement therapy (HRT) in menopausal and postmenopausal women continues to tip toward the same conclusion – that taking HRT is dangerous.
The U.S. Supreme Court has rejected an appeal from Pfizer over its hormone replacement therapy (HRT) Prempro, which means the pharmaceutical company will have to pay three Nevada women nearly $58 million. Pfizer claimed that plaintiffs attorneys biased the jury during closing arguments, which led to the jury awarding $134.1 to the three women. That award was later reduced to $57.6 million.
For years, Mrs. Smith* chose not to take hormone replacement therapy (HRT) to treat bothersome symptoms of menopause. During menopause, some women become “estrogen deficient” – their estrogen level drops so low that they experience symptoms such as hot flashes, night sweats and vaginal dryness that can be so severe it interferes with a woman’s quality of life.
Mrs. Smith talked to her doctor, who recommended Prempro, a pill made by Wyeth that contains a mixture of estrogen and synthetic progestin hormones. The pills were also marketed to doctors and women as a miracle drug that tamed not only menopausal symptoms but also had the added benefit of protecting women against heart disease and osteoporosis. HRT became widely prescribed, and Wyeth racked in billions in profits.
New research on hormone replacement therapy (HRT) and birth control pills could leave women even more confused about the risks and benefits of the drugs, doctors warn. The research, published in the Journal of NeuroInterventional Surgery, suggests that pills containing estrogen may help lower the risk for brain aneurysms. The news follows a tidal wave of studies that linked HRT to breast cancer and other deadly conditions including ovarian cancer, non-Hodgkin’s lymphoma, heart attack, stroke and blood clots.
Depo-Provera (medroxyprogesterone acetate), the injectable contraceptive, has updated its safety label to include warnings of breast cancer risk and bone mineral density loss. The new label changes were approved by the Food and Drug Administration (FDA) and will go into effect immediately.
A study involving nearly 58,000 women in France over a 12-year period suggests that hormone replacement therapy (HRT) may increase a woman’s risk of developing asthma after menopause. Researchers from the Gustave Roussy Institute in France and the Instituto Nacional de Salud Publica in Mexico published the findings in the British medical journal, Thorax. The study suggested that women who took HRT were 21 percent more likely to develop asthma than women who did not take HRT. The risk was even greater for women who took estrogen-only HRT compared to the combined estrogen-plus-progestin therapy, with the estrogen-only group at 54 percent greater risk of developing asthma compared to women who did not take HRT. This is the first long-term, large-scale study to suggest that estrogen-only HRT puts women at much greater risk of asthma than the combined therapy.
There is plenty of bad press about hormone replacement therapy (HRT), a striking reversal of just a decade or two ago, when drug makers were touting the many benefits of HRT for menopausal women. Those drug makers spent millions of dollars developing advertising campaigns and paying doctors to write articles in medical journals claiming the pills that combined estrogen and progestin were the fountain of youth. They put an end to nasty menopause symptoms such as mood swings and hot flashes, and offered the added benefit of strengthening bones and protecting women against cancer and heart disease.
Drug companies’ advertisements touting the benefits of hormone replacement therapy (HRT) sold Delores Ann Spann Whatley of Tyler, Texas on the idea that her mood swings and hot flashes could be wiped away with just a daily pill. The estrogen-and-progestin cocktail was touted as a miracle drug, able to squash menopause symptoms while warding against osteoporosis, heart disease and cancer. But the pharmaceutical companies soon realized that the HRT that was making them rich was actually making consumers sick. But instead of notifying the public and pulling their product, the drug companies attempted to cover up the mounting statistics and continued to advertise to women about the benefits of HRT.
Women who took Wyeth’s hormone replacement therapy (HRT) Prempro at least five years are at greater risk of dying from non-small cell lung cancer, according to a recent study presented at an American Society of Clinical Oncology meeting.
The Food and Drug Administration (FDA) is expected to issue a warming to doctors about an increased risk of the recurrence of breast cancer with patients taking both the breast cancer drug tamoxifen and select antidepressants, according to a study released last week at the American Society of Clinical Oncology’s annual meeting.
